Penserra Capital Management LLC Ligand Pharmaceuticals Inc Transaction History

Penserra Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $695,041 - $1.11 Million	-7,317 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$127.69 - $165.85 $885,785 - $1.15 Million	6,937 Added 1825.53%	7,317 $1.13 Million
Q2 2021 Aug 12, 2021	SELL	$113.03 - $155.64 $1.8 Million - $2.48 Million	-15,958 Reduced 97.67%	380 $49,000
Q1 2021 May 13, 2021	BUY	$99.52 - $215.83 $1.59 Million - $3.45 Million	15,968 Added 4315.68%	16,338 $2.49 Million
Q4 2020 Feb 12, 2021	BUY	$80.55 - $106.05 $18,687 - $24,603	232 Added 168.12%	370 $36,000
Q3 2020 Nov 13, 2020	BUY	$89.56 - $126.72 $12,359 - $17,487	138 New	138 $13,000
Q4 2018 Feb 06, 2019	SELL	$128.36 - $272.13 $9.44 Million - $20 Million	-73,513 Closed	0 $0
Q3 2018 Nov 05, 2018	BUY	$211.18 - $274.49 $595,738 - $774,336	2,821 Added 3.99%	73,513 $20.2 Million
Q2 2018 Aug 13, 2018	BUY	$150.77 - $207.98 $4.2 Million - $5.79 Million	27,838 Added 64.96%	70,692 $14.6 Million
Q1 2018 May 08, 2018	BUY	$138.63 - $182.62 $5.94 Million - $7.83 Million	42,854 New	42,854 $7.08 Million

255

18.1M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.86B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.